Clinical Trial Update: Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating adipose-derived mesenchymal stem cells to treat rejection in kidney transplant recipients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection
• Kidney Transplantation

Drugs mentioned

• Adipose-derived mesenchymal stem cells

Snippet

Sponsor: Mayo Clinic | Conditions: Kidney Transplant | Phase 1 | Status: RECRUITING